<DOC>
	<DOCNO>NCT02514239</DOCNO>
	<brief_summary>The primary objective part A open label phase I dose escalation study determine maximum tolerate dose ( MTD ) BI 836909 administer continuous i.v . infusion patient relapse and/or refractory multiple myeloma . The primary objective part B open label , phase I , dose escalation study determine maximum tolerate dose ( MTD ) BI 836909 give daily subcutaneous injection patient relapse and/or refractory multiple myeloma . The secondary objective part study : 1 . Recommended dos development Phase II 2 . To provide preliminary finding safety profile assess pharmacokinetic profile BI 836909 3 . To assess pharmacodynamic anti-tumoral activity BI 836909 ...</brief_summary>
	<brief_title>Phase I Dose Escalation i.v . s.c. BI 836909 Monotherapy Last Line Multiple Myeloma Patients</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Inclusion criterion : Patients document diagnosis relapse and/or refractory multiple myeloma progress least two prior treatment regimen , include proteasome inhibitor well immunemodulatory drug time screen must measurable disease , define one follow time screen : serum M protein &gt; 0.5 g/dl measure b serum protein electrophoresis urinary M protein excretion &gt; 200 mg/24 hour serum free light chain ( FLC ) measurement &gt; 10 mg/dl . provide serum FLC ratio abnormal Relapse progression disease indication therapy per investigatorÂ´s judgement time screen ECOG Performance Status 0 , 1 2 time screen Age &gt; = 18 year time screen Written informed consent consistent ICH_GCP guideline local legislation Able adhere study visit schedule e.g . ability come clinic protocol requirement For part A : indwelling central venous cateder willingness undergo intra venous central line placement . Exclusion criterion : Plasma cell leukemia Extramedullary relapse multiple myeloma Known central nervous system involvement multiple myeloma Last anticancer treatment &lt; 2 week prior visit 1 Last treatment therapeutic antibody le 6 week prior visit 1 Prior allogeneic stem cell transplantation solid organ transplantation Autologous bone marrow transplantation &lt; 90 day time treatment start Last corticosteroid &lt; 2 week prior visit 1 unless dose &lt; = 10 mg/day prednisolone equivalent AST ALT &gt; 3 x upper limit normal ( CTCAE version 4.03 grade 2 high ) time screen Total conjugate bilirubin &gt; 1.5 x upper limit normal ( CTCAE version 4.03 grade 2 high ) time screen Absolute neutrophil count &lt; 1.0 x 109/L ( without growth factor support ) time screen Platelets &lt; 25 x 109/L ( without transfusion ) time screen Calculated GFR &lt; 30 mL/min ( CockcroftGault Formula ) time screen Clinical relevant concurrent medical disease condition accord investigator ` judgement would either compromise patient safety interfere evaluation safety test drug , e.g . symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia require therapy time screen clinically control chronic ongoing infectious disease require treatment time enrolment within previous two week Active hepatitis B C , laboratory evidence chronic infection hepatitis B C time screen ; HIV infection time screen Women childbearing potential use highly effective method birth control trial one year last dose . Highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly used implant , injectables , combine oral contraceptive , intrauterine devise ( IUDs ) , sexual abstinence vasectomise partner . Barrier method contraception accept condom occlusive cap use together spermicide ( e.g . foam , gel ) . Female patient consider childbearing potential unless surgically sterilize hysterectomy bilateral tubal ligation/salpingectomy , postmenopausal ( 12 month menses without alternative medical cause Male patient partner childbearing potential unwilling use condom combination second medically acceptable method contraception trial minimum 6 month treatment Pregnancy breast feed Known suspect active alcohol drug abuse per investigator ` judgement Treatment another investigational drug within past four week start therapy concomitantly trial Patients know hypersensitivity comonent study drug Patients malignancy within 5 year time screening ( except basal cell squamous cell carcinoma skin carcinoma situ treat curative therapy ) Known autoimmune disease require systemic treatment past 5 year interfere evaluation study drug Preexisting disorder central nervous system</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>